IMed Group has appointed Parminder Kalle as its new Chief Commercial Officer.
He brings over 20 years of experience across medical devices, in vitro diagnostics (IVDs), pharma and digital health, combining technical expertise with a proven track record in commercial leadership.
In his new role, he will lead IMed Group’s business development and strategic growth initiatives globally.
Parminder joins IMed Group with a mission to accelerate the company’s international growth, build strategic partnerships and enhance the integration of IMed Group’s quality, regulatory and clinical services
As CCO, Parminder will oversee all aspects of commercial operations, focusing on three core service areas: quality, regulatory and clinical services.
“IMed Group is entering an exciting phase of evolution,” said Parminder. “Our strength lies in combining deep regulatory expertise with commercial strategy. My focus is on driving growth through meaningful partnerships and helping our clients adapt quickly to industry change, turning compliance and quality into a platform for long-term success.”
“Parm brings a rare combination of technical expertise, commercial acumen and international experience” said Leeanne Baker, CEO of IMed Group. “His appointment strengthens our ability to deliver innovative, client-focused solutions across the global life sciences sector. We are confident that his leadership will enable IMed Group to grow further while continuing to provide outstanding support to our clients.”